{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:04:11Z","timestamp":1774073051397,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0118569","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T20:11:50Z","timestamp":1426623110000},"page":"e0118569","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"isrctn17030426","registry":"10.18810\/isrctn"}],"author":[{"given":"Amelia O.","family":"Clive","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare E.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Edey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna J.","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Zahan-Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Lyburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy P.","family":"Braybrooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iara","family":"Sequeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Lyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Milton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan C.","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick A.","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,3,17]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","article-title":"Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature","volume":"38","author":"M Gnant","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","article-title":"Bisphosphonates&apos; antitumor activity: an unravelled side of a multifaceted drug class","volume":"48","author":"P Clezardin","year":"2011","journal-title":"Bone"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-05-2766","article-title":"Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo","volume":"12","author":"S Wakchoure","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2010.02.008","article-title":"A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro","volume":"294","author":"E Kawata","year":"2010","journal-title":"Cancer Lett"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"JD Veltman","year":"2010","journal-title":"Br J Cancer"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","article-title":"Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S-Phase Arrest in p53-Independent and Ras prenylation-Independent Manners","volume":"7","author":"S Okamoto","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1164\/rccm.200710-1513OC","article-title":"Zoledronic acid is effective against experimental malignant pleural effusion","volume":"178","author":"GT Stathopoulos","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","unstructured":"EORTC. EORTC QLQ-C30 Scoring Manual. 2001. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eortc.be\/qol\/files\/SCManualQLQ-C30.pdf\" xlink:type=\"simple\">http:\/\/www.eortc.be\/qol\/files\/SCManualQLQ-C30.pdf<\/ext-link> (accessed 19th Sept 2014)."},{"key":"ref9","unstructured":"Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics- zoledronic acid. 2012. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.medicines.org.uk\/emc\/medicine\/14062\" xlink:type=\"simple\">http:\/\/www.medicines.org.uk\/emc\/medicine\/14062<\/ext-link> (accessed 9th August 2012)."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1745-6215-15-139","article-title":"The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies","volume":"15","author":"BC Kahan","year":"2014","journal-title":"Trials"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/sim.4431","article-title":"Improper analysis of trials randomised using stratified blocks or minimisation","volume":"31","author":"BC Kahan","year":"2012","journal-title":"Statistics in Medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e5840","DOI":"10.1136\/bmj.e5840","article-title":"Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis","volume":"345","author":"BC Kahan","year":"2012","journal-title":"BMJ"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/sim.1981","article-title":"Adjusting for partially missing baseline measurements in randomized trials","volume":"24","author":"IR White","year":"2005","journal-title":"Stat Med"},{"issue":"6719","key":"ref14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.300.6719.230","article-title":"Analysis of serial measurements in medical research","volume":"300","author":"JN Matthews","year":"1990","journal-title":"BMJ"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"ref16","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"JP van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"M Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"e60297","DOI":"10.1371\/journal.pone.0060297","article-title":"Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels","volume":"8","author":"S Okamoto","year":"2013","journal-title":"PLoS ONE"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/01.COT.0000383778.58160.53","article-title":"Speak Up: Reflections from a Nightmare Patient\u2014Me!","volume":"32","author":"A Lawson","year":"2010","journal-title":"Oncology Times"},{"key":"ref20","unstructured":"Bushunow P. Zometa Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01004510?sect=X740156\" xlink:type=\"simple\">http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01004510?sect=X740156<\/ext-link> (accessed 19th August 2014)."},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/JTO.0b013e318208c83d","article-title":"A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria","volume":"6","author":"AS Tsao","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"MJ Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/JTO.0000000000000211","article-title":"Byrne MJ. Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions","volume":"9","author":"SG Armato 3rd","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1378\/chest.129.6.1570","article-title":"Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome","volume":"129","author":"FL Giesel","year":"2006","journal-title":"Chest"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1148\/radiol.12110872","article-title":"Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging\u2014initial experience","volume":"263","author":"J Coolen","year":"2012","journal-title":"Radiology"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"A Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","volume":"75","author":"SC Kao","year":"2012","journal-title":"Lung Cancer"},{"issue":"8","key":"ref29","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"D Santini","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-12-3235","article-title":"Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer\u2014a randomized biomarker pilot study","volume":"19","author":"MC Winter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref31","unstructured":"Robert F. Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB0901). 2014. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/show\/NCT01204203\" xlink:type=\"simple\">http:\/\/clinicaltrials.gov\/show\/NCT01204203<\/ext-link> (accessed 10th October 2014)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0118569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:10:59Z","timestamp":1588993859000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0118569"}},"subtitle":[],"editor":[{"given":"Eng-Huat","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,17]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0118569","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,17]]}}}